Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Pumpers don't get holidays....so expect Clown here all summe

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon May 31, 2022 6:38pm

88 Views

Post# 34721592

RE:Pumpers don't get holidays....so expect Clown here all summe

predictions?! Lol your account is 6 months old to troll mugs. What predictions have you made? Lmao!

Stutters wrote:
.45 cents by end of summer. That's my prediction. I hope it happens but I have been wrong before. Guess time will tell. At least I'm more accurate in my predictions than Mugsy Clown

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal